Racial/Ethnic and Gender Disparities in Renal Cell Carcinoma Incidence and Survival

Helen Shi Stafford,* Sidney L. Saltzstein, Suzuho Shimasaki, Catherine Sanders, Tracy M. Downs and Georgina Robins Sadler

From the Rebecca and John Moores UCSD Cancer Center (HSS, SLS, SS, CS, TMD, GRS), University of California, San Diego Medical Center, Department of Surgery/Division of Urology (TMD) and Department of Surgery/Division of General Surgery (GRS), University of California, San Diego School of Medicine (HSS, SLS), La Jolla, University of California, Los Angeles School of Public Health, Los Angeles (SS), Department of Surgery/Urology Section, Veterans Affairs San Diego Healthcare System (TMD), San Diego, California, and Ohio State University College of Medicine, Columbus, Ohio (CS)

Purpose: We used a population based cancer registry to examine trends in renal cell carcinoma incidence and survival among 4 racial/ethnic groups (white, black, Hispanic and Asian/Pacific Islander) and both genders.

Materials and Methods: Race/ethnicity, gender, age, staging, length of survival and cause of death data were analyzed using 39,434 cases of renal cell carcinoma from 1988 to 2004 from the California Cancer Registry. Annual age adjusted incidence rates and relative survival rates were calculated for the racial/ethnic and gender groups. These rates and the percent of localized cancers noted were plotted by year, and Microsoft Excel® was used to calculate linear regression equations. Median age was also calculated. Z-tests and chi-square tests were performed to determine p values.

Results: An increase in renal cell carcinoma incidence was found with localized cancer accounting for most of the increase. Black patients had a significantly higher incidence rate (p < 0.0001) and lower survival rate (p < 0.0001) than all other races/ethnicities despite having more localized cancer (p < 0.005). Black patients were also diagnosed at a younger age (p < 0.0001) than their counterparts. On the other hand Asian/Pacific Islanders had a lower incidence rate (p < 0.0001) and higher survival rate (p < 0.05) than all other races/ethnicities. Males had approximately twice the incidence rate of females and a lower survival rate (p < 0.005).

Conclusions: Higher incidence rates and lower survival rates were identified among black and male patients compared to their counterparts, while Asian/Pacific Islanders showed the opposite trends. Such racial/ethnic and gender disparities in renal cell carcinoma incidence and survival may help elucidate biological, behavioral and environmental factors that can potentially be addressed.

Key Words: kidney neoplasms, continental population groups, sex, incidence, survival rate

Renal cancer was estimated to be responsible for approximately 51,190 new cancer cases in the United States in 2007, making it the 7th most common cancer among men. It was also estimated to have caused 12,890 deaths.1 Of these renal cancers renal cell carcinoma (also called renal cell adenocarcinoma, clear cell cancer of the kidney, hypernephroma, and Grawitz tumor) accounted for 85%, while renal pelvis cancer accounted for most of the remainder.2 Renal cell carcinoma and renal pelvis cancer have been shown to have distinct epidemiology, histology, therapy and natural history.3 We focused exclusively on RCC because it is the predominant form of renal cancer and occurs in sufficient numbers to permit in-depth analysis.

RCC is twice as common in men than in women,4 with the average age at diagnosis in the early 60s.5 Studies have shown that having a first degree relative with any kidney cancer is associated with a 2 to 3-fold increased risk.6 Smoking, hypertension and obesity have also been strongly associated with RCC.5,7 The only consistently reported dietary risk factor has been a lack of fruit and vegetable consumption.5

Recent epidemiological studies have suggested that the incidence rate of RCC is increasing predominantly accounted for by localized cancer.5,8-12 Data from the National Cancer Institute’s SEER program showed that the incidence rate of RCC has increased more rapidly in black than white patients and in females than males.5,8,9 Differences between the survival rates of black and white patients were also found, but the results were confounded by factors such as socioeconomic disparities, performance status and comorbid conditions.8

See Editorial on page 1657.

For another article on a related topic see pages 2010 and 2057.
This study attempts to confirm recent reports of disparities in incidence and survival between black and non-Hispanic white patients with RCC using data from the CCR from 1988 to 2004. Additionally, the diverse demographics of California allow Hispanic and A/PI populations to be included in the study in sufficient numbers for analysis. Incidence and survival data were also analyzed by gender for each of the racial/ethnic groups and the overall patient population.

MATERIALS AND METHODS

Database

The data used for this project came from the California Cancer Registry, which has been the repository for all incident cancer cases in the state of California since 1988. A major benefit of using the CCR is its consistent population base. Previous studies have used SEER program data between 1975 and 2002. During this period the data coverage expanded from 9 to 11 to 13 regions. Two of the added regions were Los Angeles County and San Jose-Monterey, California, which may have greatly altered the racial/ethnic distribution. On the other hand, this study used a database which contains state-mandated reports of all cancer cases in California since 1988.

New cancer cases are reported to the CCR by physicians, health facilities, laboratories, nursing homes, autopsies and death certificates. There are penalties for the failure to report new cases. Cases are abstracted by Certified Cancer Abstractors. Ten regional cancer registries serve as receiving facilities and report to the central registry. Tasks such as quality assurance and the removal of duplicate entries are completed at the regional and central levels. The CCR is certified by the North American Association of Central Cancer Registries, and now the entire state is part of the SEER program. Thus, the CCR uses the same histological codes as does the SEER program. Currently, complete data are available from 1988 to 2004.

Statistical Methods

All patients diagnosed with RCC (ie cancers originating from the kidney, excluding those of the renal pelvis) were chosen from the database. The variables selected for further analysis were race/ethnicity (white, black, Hispanic or A/PI), gender, stage at time of diagnosis (localized, regional, or distant), age at diagnosis, length of survival after diagnosis and cause of death.

Annual age-adjusted incidence rates and relative survival rates for the first 10 years following diagnosis were analyzed using standard statistical analytical tools.13 Annual incidence rates, survival rates and percent of localized cancer were plotted by year, and Microsoft Excel® was used to calculate linear regression equations. Median age at diagnosis was also calculated. Z-tests and chi-square tests were used to determine p values.

Analysis for each variable was conducted after excluding the cases in which the variable was categorized as unknown. Gender was known for all cases, and the percentage of unknown data was 0.0% (739,434) for age, 0.6% (227/39,434) for race/ethnicity and 5.2% (2,062/39,434) for stage.

RESULTS

Incidence Trends

From 1988 to 2004 a total of 39,434 cases of RCC were reported to the CCR. Table 1 lists these cases by race/ethnicity and gender. Annual AAIRs were computed for the total population, and the gender and racial/ethnic groups. The AAIRs were plotted for each year, and linear regression equations were calculated to determine the slope (figs. 1 and 2).

For the total population the slope of the linear regression equation was 0.15. On average, male incidence rates were about twice that of females (fig. 1). The slopes in figure 1 show that the incidence rate of males also increased at approximately twice the rate of females. As shown in figure 2 incidence rates for blacks vs all other races/ethnicities were found to be significantly higher (z = 9.02, p <0.0001) and to have increased more rapidly with a slope of 0.21. This was also true for Hispanics, although to a slightly lesser extent (z = 11.31, p <0.0001, slope of 0.20). Incidence rates were found to be significantly lower in A/PIs than in the total population (z = 4.67, p <0.0001). Whites showed a slightly higher incidence rate than the total population (z = 3.92, p <0.001), although the statistical significance is most likely due to the large sample size.

The percent of RCC cases found to be localized at diagnosis increased steadily from 1988 to 2004 with a slope of 0.93 (fig. 3). Percent localized cancer was also plotted for the 2 genders. Overall, females showed a significantly higher percent of localized cancer than males (chi-square 59.7, p <0.0001). Males had a greater rate of increase of percent localized cancer (slope 0.98) than females (slope 0.93). When the individual racial/ethnic groups were explored, tremendous year-to-year variation within the groups made graphing unproductive. However, table 2 lists the overall percent

<p>| Table 1. Number of patients by race/ethnicity and gender |</p>
<table>
<thead>
<tr>
<th>No. Male</th>
<th>No. Female</th>
<th>Totals</th>
</tr>
</thead>
<tbody>
<tr>
<td>White</td>
<td>17,652</td>
<td>9,652</td>
</tr>
<tr>
<td>Black</td>
<td>1,738</td>
<td>1,024</td>
</tr>
<tr>
<td>Hispanic</td>
<td>4,263</td>
<td>2,892</td>
</tr>
<tr>
<td>Asian/Pacific</td>
<td>1,282</td>
<td>702</td>
</tr>
<tr>
<td>Islander</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other/unknown</td>
<td>146</td>
<td>83</td>
</tr>
<tr>
<td>Totals</td>
<td>25,081</td>
<td>14,353</td>
</tr>
</tbody>
</table>

![Fig. 1. Age adjusted incidence rate of RCC from 1988 to 2004 by gender.](image-url)
of localized, regional and distant cancer for each racial/ethnic and gender group. Localized and regional cancer varied between the groups whereas distant cancer was relatively constant. Black patients had a significantly higher percent of localized cancer compared to all other patients (chi-square 19.3, p < 0.005). On the other hand, white patients had a statistically significantly lower percent of localized cancer compared to all other patients (chi-square 6.08, p < 0.025).

The median age at diagnosis by race/ethnicity and gender is shown in Table 3. Significant differences in age at diagnosis were found between males and females (z = 8.92, p < 0.0001). Black and Hispanic patients had the same median age at diagnosis of 61 years, which was significantly lower than their respective counterparts (z = 11.4, p < 0.0001 and z = 22.8, p < 0.0001, respectively). A/PIs also had a significantly lower median age at diagnosis of 63 years vs their counterparts (z = 4.67, p < 0.0001). White patients had a higher median age at diagnosis of 66 years compared to all other races/ethnicities (z = 28.6, p < 0.0001).

Survival Analysis
Relative survival rates for the first 10 years after diagnosis are shown in Figure 4 for the racial/ethnic groups. Relative survival rates were higher for A/PIs (z = 1.96, p = 0.05) and significantly lower for black patients (z = 6.43, p < 0.0001) compared to their counterparts. Relative survival rates were also significantly higher for females than for males (z = 3.06, p < 0.005).

Relative survival rates for patients with localized RCC by racial/ethnic group are shown in Figure 5. Comparing only localized RCC augmented the difference in survival between black patients and all other groups. Table 4 shows the causes of death for the study population divided into racial/ethnic and gender groups. Cause of death is listed as neoplasm specific for approximately a third of RCC deaths, and of those neoplasm deaths approximately 80% were listed as kidney specific. Approximately 10% of patients who died did not have a death certificate available to establish the cause of death. White patients had a significantly higher percentage of neoplasm as the cause of death compared to the other races/ethnicities, while Hispanics and A/PIs had fewer death certificates available.

DISCUSSION
The current analysis shows that annual age adjusted incidence rates of RCC among Californians have increased steadily between 1988 and 2004. As shown in previous studies, localized cancer accounted for most of the increased incidence. This may largely be due to increased incidental detection of RCC, resulting from the growing use of ultrasound and CT for nonrenal cancer related problems. Risk factors such as smoking, hypertension, obesity and diet have been associated with RCC, and may have a role in the increasing incidence. Of these factors, smoking prevalence has decreased over time and, therefore, may not explain the increasing incidence of RCC. However, the prevalence of obesity has increased significantly over time and could be contributing to the increased incidence.

Black patients were found to have a significantly higher incidence rate than all other races/ethnicities. They were also diagnosed at a younger age with more localized (low stage) cancer. It would be unlikely for this higher incidence rate to be explained by increased incidental detection since black patients tend to have less access to health care for undergoing ultrasound and CT.

Table 3 shows the median age at diagnosis by gender and race/ethnicity.
patient. Black patients also have a much higher prevalence of hypertension at a younger age, which is a significant risk factor for developing RCC. Overall greater environmental stress experienced by the black community may also contribute to increased incidence of RCC.

Despite having more localized cancer black patients with RCC still have a significantly lower survival rate than all other races/ethnicities. This decrease in survival is augmented when comparing only localized RCC. Previous studies have also shown this disparity, while acknowledging confounding factors such as comorbidities. Other studies have attempted to account for comorbidities by analyzing death certificate cause of death data to isolate cancer specific deaths. However, death certificate accuracy is often as low as 40% due to wording inaccuracies and lack of training among physicians. Because of this and because 10% of the patients in this study did not even have a death certificate available, it was decided that the cause of death data were not an effective means for accounting for comorbidities.

Instead, relative survival data were used to account for other causes of death that would be present in the general population for each gender and age. Relative survival rates confirmed that black patients do not survive as well as their nonblack counterparts. This is true although black patients are diagnosed with more localized cancer. It was also noted that black patients are diagnosed at a younger age, a circumstance that should give them more resilience in the face of aggressive treatments, but may suggest the presence of a more aggressive cancer. This observed disparity in survival rates for black patients may also be due in part to lack of access to treatment and additional stressors associated with lower socioeconomic status. Moreover, Berndt et al showed that the difference in survival between black and white patients with RCC can be substantially reduced by accounting for comorbidities and the lower likelihood of receiving nephrectomy treatment among black patients.

On the other hand, A/PIs were found to have a significantly lower annual age-adjusted incidence rate and a higher relative survival. This is consistent with trends in overall cancer incidence and survival among A/PIs in California reported in 2003. This may partly be due to the higher percentage of localized cancers diagnosed among A/PIs. Other factors could include differences in tumor aggressiveness, comorbid diseases, cultural behaviors, and access to and use of the health care system. However, it is important to note that different Asian ethnic subgroups often have different cancer burdens, which may skew the overall trends in the A/PI population.

As previously reported, males were found to have approximately twice the incidence rate of females. However, contrary to previous reports, male incidence rates appeared to increase more rapidly than female incidence rates. This new trend may be related to increasing localized cancer incidence, since localized cancer was also shown to have increased more rapidly among males than females. Additionally, males were found to have a lower relative survival rate than females. This may be a result of the higher percent of localized cancer among females. A 2002 study suggested that the difference between male and female survival rates may be due to more extensive use of the health care system by females than males. Other potential causes of this observed disparity include biological differences in the tumor and in male vs female patients, as well as the higher prevalence of hypertension in males vs females.

As with most studies the findings of this study must be generalized with caution. Gaps in data completeness for staging and, to a much lesser extent, race/ethnicity may affect accuracy. Additionally, comorbidity data are not available in the CCR, which could influence the disparities in survival.

**CONCLUSIONS**

The incidence of RCC in California has increased steadily between 1988 and 2004, with localized cancer accounting for most of that increase. Significant differences in incidence rates and survival rates were observed among racial/ethnic
and gender groups. Black patients had a significantly higher incidence rate and lower relative survival rate than all other races/ethnicities, while Asians/Pacific Islanders showed just the opposite. Males had twice the incidence rate and a slightly lower relative survival rate than females. Identification of such racial/ethnic and gender disparities in RCC incidence rates and survival rates may help elucidate biological, behavioral, and environmental factors that can potentially be addressed.

### Abbreviations and Acronyms

- AAIRs: annual age adjusted incidence rates
- API: Asian/Pacific Islander
- CCR: California Cancer Registry
- CT: computerized tomography
- RCC: renal cell carcinoma
- SEER: Surveillance, Epidemiology, and End Results Program

### REFERENCES